T-type calcium channel inhibitor

Abstract

The present invention provides a T-type calcium channel inhibitor which is a compound represented by formula (1), a pharmaceutically acceptable salt of this compound or a solvate of this compound. The present invention also provides: this T-type calcium channel inhibitor; a pharmaceutical product containing this T-type calcium channel inhibitor; and a therapeutic agent or prophylactic agent for diseases, the effective action of which is a T-type calcium channel inhibitory action. (In formula (1), each of R 1 and R 2 independently represents H, —OH or —OR 11 , wherein R 11 represents a C 1-3 alkyl group; each of R 3 and R 4 independently represents H, —OH or —OR 12 , wherein R 12 represents a C 1-3 alkyl group; and each of R 5 and R 6 independently represents H, a halogen atom, a C 1-10 alkyl group, a C 2-6 alkenyl group, a C 2-6 alkynyl group, a phenyl group (which may be substituted by a C 1-6 alkoxy group or a halogen atom), a —C 1-3 alkyl-phenyl group (which may be substituted by a C 1-6 alkyloxy group or a halogen atom) or a C 10-50 prenyl group.)

1 . A T-type calcium channel inhibitor, wherein the T-type calcium channel inhibitor is a compound represented by the formula (1): 
       
         
           
           
               
               
           
         
         [wherein each of R 1  and R 2  independently represents H, —OH, or —OR 11  wherein R 11  represents a C 1-3  alkyl group; 
         each of R 3  and R 4  independently represents H, —OH, or —OR 12  wherein R 12  represents a C 1-3  alkyl group; 
         R 5  represents a C 2-6  alkenyl group, a 3,7-dimethyl-2,6-octadienyl group or a 5-methyl-2-(1-methylethenyl)-4-hexenyl group; and 
         R 6  represents H], 
         a pharmaceutically acceptable salt of the compound, or a solvate of the compound. 
       
     
     
         2 . (canceled) 
     
     
         3 . The T-type calcium channel inhibitor of  claim 1 , wherein each of R 1  and R 2  independently represents H, or —OH;
 each of R 3  and R 4  independently represents —OH, or —OR 12  wherein R 12  represents a C 1-3  alkyl group; 
 R 5  represents a C 2-6  alkenyl group, a 3,7-dimethyl-2,6-octadienyl group or a 5-methyl-2-(1-methylethenyl)-4-hexenyl group; and 
 R 6  represents H. 
 
     
     
         4 . The T-type calcium channel inhibitor of  claim 1 , wherein each of R 1  and R 2  independently represents H or —OH;
 each of R 3  and R 4  independently represents —OH; 
 R 5  represents a C 2-6  alkenyl group, a 3,7-dimethyl-2,6-octadienyl group or a 5-methyl-2-(1-methylethenyl)-4-hexenyl group; and 
 R 6  represents H. 
 
     
     
         5 . A pharmaceutical product containing the T-type calcium channel inhibitor of  claim 1 . 
     
     
         6 . A therapeutic agent or prophylactic agent for neuropathic pains, which contains the T-type calcium channel inhibitor of  claim 1 . 
     
     
         7 . A T-type calcium channel inhibitor, which is (2S)-5,7-dihydroxy-2,3-dihydro-2-(2,4-dihydroxyphenyl)-8-[(R)-5-methyl-2-(1-methylethenyl)-4-hexenyl]-4H-1-benzopyran-4-on e, (2S)-5,7-dihydroxy-2,3-dihydro-2-(2,4-dihydroxyphenyl)-6-[(R)-5-methyl-2-(1-methylethenyl)-4-hexenyl]-4H-benzopyran-4-one, (2S)-5,7-dihydroxy-2,3-dihydro-2-(4-hydroxyphenyl)-6-(3-methyl-2-butenyl)-4H-1-benzopyran-4-one or (2S)-5,7-dihydroxy-2-(3-hydoxy-4-methoxyphenyl)-2,3-dihydro-4H-chromen-4-one. 
     
     
         8 . A pharmaceutical product containing the T-type calcium channel inhibitor of  claim 7 . 
     
     
         9 . A therapeutic agent or prophylactic agent for neuropathic pains, which contains the T-type calcium channel inhibitor of  claim 7 .